Teva unveils promising SOLARIS resultsfor Olanzapine LAI
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Importantly, the combination of giredestrant and everolimus was well tolerated
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Subscribe To Our Newsletter & Stay Updated